Aptose Biosciences Inc. (APTO) Reaches $2.86 52-Week High; PARTNERS GROUP (PGPHF) Sellers Increased By 1.46% Their Shorts

January 16, 2018 - By Richard Conner

The stock of Aptose Biosciences Inc. (NASDAQ:APTO) hit a new 52-week high and has $3.12 target or 9.00% above today’s $2.86 share price. The 8 months bullish chart indicates low risk for the $74.11 million company. The 1-year high was reported on Jan, 16 by Barchart.com. If the $3.12 price target is reached, the company will be worth $6.67M more. The stock increased 15.38% or $0.3814 during the last trading session, reaching $2.8614. About 443,577 shares traded. Aptose Biosciences Inc. (NASDAQ:APTO) has declined 60.81% since January 16, 2017 and is downtrending. It has underperformed by 77.51% the S&P500.

PARTNERS GROUP (OTCMKTS:PGPHF) had an increase of 1.46% in short interest. PGPHF’s SI was 55,700 shares in January as released by FINRA. Its up 1.46% from 54,900 shares previously. With 100 avg volume, 557 days are for PARTNERS GROUP (OTCMKTS:PGPHF)’s short sellers to cover PGPHF’s short positions. The stock increased 2.98% or $21.7 during the last trading session, reaching $750.7. About 10 shares traded. Partners Group Holding AG (OTCMKTS:PGPHF) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $74.11 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Analysts await Aptose Biosciences Inc. (NASDAQ:APTO) to report earnings on March, 27. They expect $-0.14 EPS, up 26.32% or $0.05 from last year’s $-0.19 per share. After $-0.11 actual EPS reported by Aptose Biosciences Inc. for the previous quarter, Wall Street now forecasts 27.27% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By : XYZScripts.com